Search Results

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure N.V. announced that it has entered into an agreement for the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus technologies.

July 1, 2024

·

7 min read

Genezen to Acquire uniQure’s Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Genezen, a best-in-class gene therapy CDMO, announced an agreement to acquire uniQure’s commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

July 1, 2024

·

3 min read

Press Releases

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

November 6, 2024

·

16 min read

Pictured: uniQure headquarters in Amsterdam

Huntington’s Disease

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

Following a disappointing readout last year, uniQure on Tuesday posted promising Phase I/II data for its investigational gene therapy AMT-130 and nabbed the first-ever Regenerative Medicine Advanced Therapy designation from the FDA in Huntington’s disease.

July 9, 2024

·

2 min read

·

Tristan Manalac

Business

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the first quarter of 2024 and highlighted recent progress across its business.

May 7, 2024

·

12 min read

Press Releases

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

September 23, 2024

·

5 min read

Policy

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure N.V. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for its investigational gene therapy AMT-130 for the treatment of Huntington’s disease.

June 3, 2024

·

8 min read

Genetown

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure N.V. reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress across its business.

February 28, 2024

·

13 min read

Press Releases

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

October 15, 2024

·

5 min read

Press Releases

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

October 16, 2024

·

5 min read